Search

Your search keyword '"PORNEUF, M"' showing total 98 results

Search Constraints

Start Over You searched for: Author "PORNEUF, M" Remove constraint Author: "PORNEUF, M"
98 results on '"PORNEUF, M"'

Search Results

1. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

2. PRAISE : décrire les effets immunologiques secondaires à l’immunothérapie dans le cancer – analyse de la qualité de vie

3. Résultats intermédiaires sur les 658 premiers patients de l’étude PRAISE (Patient-Reported AutoImmunity SEcondary to cancer immunotherapy) : étude de cohorte prospective multicentrique pour le suivi des manifestations auto-immunes sous immunothérapie

4. POS1412 FIRSTS RESULTS OF THE PRAISE STUDY (PATIENT-REPORTED AUTOIMMUNITY SECONDARY TO CANCER IMMUNOTHERAPY): MULTICENTRIC PROSPECTIVE COHORT STUDY ON AUTOIMMUNE DISEASES SECONDARY TO CANCER IMMUNOTHÉRAPY

5. Premiers résultats de l’étude PRAISE (Patient-Reported AutoImmunity SEcondary to cancer immunotherapy) : étude de cohorte prospective multicentrique pour le suivi des manifestations auto-immunes survenant sous immunothérapie anticancéreuse

6. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire)

10. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†

12. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

14. Évaluation en pratique courante de l’association bevacizumab-FOLFIRI en première ligne chez des patients atteints d’un cancer colorectal métastatique non résécable traités en 2006: focus sur patients réséqués et oncogériatrie

16. Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM): Results of a retrospective cohort study of the OMIT Bretagne and Pays de la Loire.

18. NMR and more in honour of Anatole Abragam

19. Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: ALOPERS Observatory.

31. Hydroxyurea -- induced dermatomyositis -- like eruption.

32. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics

34. Nucleon-nucleon scattering at medium energies

36. Calculation of $\pi$ d-nn observables

37. $\pi$ n p$_{11}$ channel amplitude parametrizations

38. Collective masses for anharmonic isoscalar vibrations

39. Reactions de deux Nucleons sur le $^{54}$Fr et le $^{58}$Ni a l'aide d'un Faisceau de $^{16}$O de 80 MeV

40. Recoil study of Transfer Reactions Induced with $^{40}Ar in Heavy Nuclei

41. Constrained Hartree-Fock calculations of $^{240}$Pu

42. Reactions de Noyaux composes 'super-Lourds' par Spectrometrie de Masse en Vol

43. Alpha Pickup in the A=90 Region

44. Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency.

45. Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies.

46. Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus.

47. Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.

48. Metastatic melanoma: results of 'classical' second-line treatment with cytotoxic chemotherapies.

49. Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.

Catalog

Books, media, physical & digital resources